aTyr Pharma is a clinical-stage biotechnology company focused on developing therapeutics derived from tRNA synthetase biology to treat fibrosis and inflammatory diseases. The company's lead candidate, efzofitimod, is a selective modulator of neuropilin-2 (NRP2) currently in Phase 3 clinical trials for pulmonary sarcoidosis and Phase 1b/2a trials for other interstitial lung diseases, including chronic hypersensitivity pneumonitis and connective tissue disease-related ILD. The company also maintains a pipeline of earlier-stage programs: ATYR0101, a fusion protein derived from aspartyl-tRNA synthetase in preclinical development for fibrosis indications, and ATYR0750, an alanyl-tRNA synthetase domain targeting liver disorders.
aTyr operates from its headquarters in San Diego, California, with a lean organizational structure of 56 full-time employees. The company has established a collaboration and licensing agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod in Japan, providing a potential revenue stream and geographic expansion pathway. As a clinical-stage entity, the company does not currently generate product revenue and operates primarily through research and development activities supported by capital financing.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-0.86 | $-0.86 | +8.5% | |
| 2023 | $-0.94 | $-0.94 | +41.3% | |
| 2022 | $-1.60 | $-1.60 | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — | |
| 2017 | — | — | — | |
| 2016 | — | — | — | |
| 2015 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-13 | 0000950170-25-038888 | SEC ↗ |
| 2023-12-31 | 2024-03-14 | 0000950170-24-031584 | SEC ↗ |
| 2022-12-31 | 2023-03-14 | 0000950170-23-007873 | SEC ↗ |
| 2021-12-31 | 2022-03-15 | 0001564590-22-010441 | SEC ↗ |
| 2020-12-31 | 2021-03-24 | 0001564590-21-014940 | SEC ↗ |
| 2019-12-31 | 2020-03-26 | 0001564590-20-013208 | SEC ↗ |
| 2018-12-31 | 2019-03-26 | 0001564590-19-009381 | SEC ↗ |
| 2017-12-31 | 2018-03-20 | 0001564590-18-006333 | SEC ↗ |
| 2016-12-31 | 2017-03-16 | 0001564590-17-004631 | SEC ↗ |
| 2015-12-31 | 2016-03-30 | 0001564590-16-015652 | SEC ↗ |